Hospital
John Muir Health
John Muir Health was paid $32.05M by Medicaid between Jan 2018 and Dec 2024, across 296 billing codes. Its largest line is 0450, Emergency room services — 15% of everything it billed.
33Billing provider infoJOHN MUIR HEALTH
CONCORD, CA 94520
CONCORD, CA 94520
33aNPI1801821376assigned 07/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.05M
24GClaims1,106,795
24DCodes billed296
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#89 of 410
Median peer was paid$6.90M
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 150,480 | $5.77M | |
| 2019 | 139,347 | $3.22M | |
| 2020 | 108,354 | $2.48M | |
| 2021 | 142,241 | $3.40M | |
| 2022 | 164,332 | $4.42M | |
| 2023 | 179,413 | $4.34M | |
| 2024incomplete | 222,628 | $8.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 15% | 135,796 | 121,849 | $4.74M |
| J3490 | Unclassified drugs | 7.0% | 152,524 | 65,618 | $2.25M |
| J9271 | Injection, pembrolizumab, 1 mg | 4.9% | 149 | 122 | $1.57M |
| 0121 | 4.7% | 208 | 204 | $1.52M | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.9% | 4,523 | 4,486 | $1.25M |
| 0206 | 3.7% | 198 | 194 | $1.17M | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 20,144 | 18,723 | $1.15M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 5,674 | 5,577 | $1.15M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 2.4% | 113 | 80 | $780K |
| 0272 | 2.2% | 8,064 | 7,685 | $699K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 35,858 | 32,980 | $684K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.9% | 4,845 | 4,738 | $621K |
284 more codes
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 1.8% | 10,774 | $586K |
| 93976 | 1.7% | 2,778 | $537K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 11,247 | $536K |
| 80053 | Comprehensive metabolic panel | 1.6% | 54,295 | $520K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 6,383 | $498K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 65,717 | $432K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 3,855 | $383K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 13,960 | $362K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,716 | $314K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,082 | $309K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,603 | $307K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,283 | $307K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,881 | $304K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 16,112 | $304K |
| 96376 | <1% | 4,805 | $299K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,183 | $277K |
| 99199 | Unlisted special service, procedure or report | <1% | 5,306 | $275K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,660 | $274K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,994 | $224K |
| 71045 | Radiologic examination, chest; single view | <1% | 22,975 | $224K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,989 | $219K |
| 0250 | <1% | 2,447 | $209K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,697 | $201K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,834 | $196K |
| 84484 | <1% | 22,770 | $195K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,776 | $191K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,619 | $184K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,489 | $182K |
| 70498 | <1% | 947 | $181K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,193 | $179K |
| 70496 | <1% | 920 | $173K | |
| 93971 | <1% | 1,916 | $166K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,223 | $164K |
| Z7502 | <1% | 5,283 | $160K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,220 | $153K |
| 99283 | Emergency room visit (moderate) | <1% | 2,304 | $143K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,781 | $141K |
| 83690 | <1% | 23,047 | $141K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,882 | $139K |
| 76830 | Ultrasound, transvaginal | <1% | 2,796 | $137K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,168 | $120K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,802 | $118K |
| 84703 | <1% | 16,630 | $104K | |
| 99284 | Emergency room visit (serious) | <1% | 2,395 | $103K |
| 83880 | <1% | 3,979 | $101K | |
| 81001 | <1% | 34,235 | $99K | |
| 76801 | <1% | 1,481 | $94K | |
| 97162 | <1% | 2,053 | $94K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,642 | $92K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,046 | $91K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 113 | $87K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,275 | $85K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,329 | $77K |
| 94664 | <1% | 6,076 | $72K | |
| 76770 | <1% | 1,229 | $72K | |
| 84702 | <1% | 5,583 | $70K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,451 | $67K |
| 0510 | <1% | 2,796 | $61K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,079 | $61K |
| 87040 | <1% | 6,258 | $54K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,614 | $49K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 525 | $47K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 3,930 | $47K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,082 | $43K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,119 | $42K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,872 | $41K |
| J1815 | Injection, insulin, per 5 units | <1% | 2,458 | $41K |
| 93458 | <1% | 40 | $40K | |
| 83735 | <1% | 6,756 | $39K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,078 | $39K |
| 74018 | <1% | 2,233 | $36K | |
| 83605 | <1% | 4,165 | $36K | |
| 73630 | <1% | 2,083 | $36K | |
| 87077 | <1% | 5,404 | $36K | |
| 99070 | <1% | 1,693 | $34K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,630 | $34K |
| 97139 | <1% | 2,099 | $33K | |
| 73030 | <1% | 1,678 | $31K | |
| 73564 | <1% | 1,492 | $31K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 510 | $31K |
| 73610 | <1% | 1,634 | $31K | |
| 87186 | <1% | 4,415 | $30K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,976 | $30K |
| 99152 | <1% | 539 | $29K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 197 | $27K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 5,256 | $27K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 844 | $27K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 704 | $26K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 914 | $25K |
| 97014 | <1% | 2,709 | $23K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 141 | $23K |
| 85379 | <1% | 2,509 | $23K | |
| 93970 | <1% | 159 | $22K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,117 | $22K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 69 | $21K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,785 | $21K |
| 72100 | <1% | 932 | $20K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,953 | $20K |
| 85730 | <1% | 4,033 | $20K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,342 | $19K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 79 | $18K |
| 0002A | <1% | 469 | $18K | |
| 73130 | <1% | 942 | $18K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 779 | $17K |
| 85610 | <1% | 5,339 | $17K | |
| 0001A | <1% | 420 | $17K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,252 | $17K |
| 82550 | <1% | 2,942 | $16K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,511 | $16K |
| 97161 | <1% | 242 | $16K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 2,675 | $15K |
| 71250 | <1% | 164 | $14K | |
| Z7610 | <1% | 1,868 | $14K | |
| 70486 | <1% | 152 | $14K | |
| 80306 | <1% | 863 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 941 | $14K |
| 82553 | <1% | 1,342 | $14K | |
| 82803 | <1% | 1,119 | $13K | |
| 87070 | <1% | 1,671 | $13K | |
| 96367 | <1% | 361 | $12K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 523 | $12K |
| 73502 | <1% | 424 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,537 | $12K |
| 90715 | <1% | 273 | $11K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 215 | $11K |
| 84145 | <1% | 575 | $11K | |
| 76536 | <1% | 211 | $10K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,748 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,774 | $9K |
| 84439 | <1% | 1,096 | $9K | |
| 76642 | <1% | 197 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,823 | $8K |
| 73110 | <1% | 363 | $8K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,773 | $7K |
| 96523 | <1% | 133 | $7K | |
| 96417 | <1% | 261 | $7K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 61 | $7K |
| 71101 | <1% | 307 | $7K | |
| 86901 | <1% | 2,596 | $7K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 143 | $7K |
| 76870 | <1% | 180 | $7K | |
| 86140 | <1% | 1,423 | $7K | |
| 73560 | <1% | 458 | $7K | |
| 0271 | <1% | 166 | $6K | |
| 82010 | <1% | 941 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,328 | $6K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 306 | $6K |
| 86900 | <1% | 2,421 | $6K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 433 | $6K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 55 | $6K |
| 0636 | <1% | 573 | $6K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,679 | $6K |
| 96415 | <1% | 242 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,415 | $6K |
| 87210 | <1% | 1,368 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 871 | $5K |
| 77336 | <1% | 162 | $5K | |
| 90714 | <1% | 169 | $5K | |
| 87507 | <1% | 12 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 17 | $5K |
| 0420 | <1% | 315 | $5K | |
| 93017 | <1% | 84 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 665 | $4K |
| 77334 | <1% | 30 | $4K | |
| 77412 | <1% | 132 | $4K | |
| 97166 | <1% | 57 | $4K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,021 | $4K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 297 | $4K |
| 0762 | <1% | 1,053 | $4K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 272 | $4K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 19 | $4K |
| 85652 | <1% | 1,423 | $3K | |
| 73140 | <1% | 237 | $3K | |
| 73590 | <1% | 190 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 285 | $3K |
| 74174 | <1% | 13 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 868 | $3K |
| 96377 | <1% | 30 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 325 | $3K |
| 82728 | <1% | 350 | $3K | |
| 85027 | <1% | 619 | $3K | |
| 97802 | <1% | 25 | $3K | |
| 73080 | <1% | 146 | $3K | |
| 99223 | Prolong inpt eval add15 m | <1% | 40 | $3K |
| 86850 | <1% | 965 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 32 | $3K |
| 85018 | <1% | 1,309 | $2K | |
| 72040 | <1% | 128 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 470 | $2K |
| 99153 | Mod sedat endo service >5yrs | <1% | 225 | $2K |
| 80061 | Lipid panel | <1% | 220 | $2K |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 133 | $2K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 15 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 303 | $2K |
| 96401 | <1% | 184 | $2K | |
| 82565 | <1% | 503 | $2K | |
| 84132 | <1% | 590 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 134 | $2K |
| 72131 | <1% | 14 | $2K | |
| 0270 | <1% | 402 | $2K | |
| 83550 | <1% | 319 | $2K | |
| 82247 | <1% | 349 | $2K | |
| 85014 | <1% | 751 | $1K | |
| 83540 | <1% | 326 | $1K | |
| 72070 | <1% | 60 | $1K | |
| 97116 | <1% | 114 | $1K | |
| 84450 | <1% | 257 | $1K | |
| 84075 | <1% | 257 | $1K | |
| 82040 | <1% | 255 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 17 | $1K |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $1K |
| 36600 | <1% | 366 | $1K | |
| 72110 | <1% | 31 | $1K | |
| 96368 | <1% | 61 | $1K | |
| 83615 | <1% | 218 | $998.45 | |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $962.09 |
| 84100 | <1% | 241 | $926.01 | |
| 84155 | <1% | 257 | $885.10 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 13 | $885.06 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 845 | $828.12 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 41 | $776.97 |
| 80047 | <1% | 108 | $760.78 | |
| 96402 | <1% | 83 | $697.75 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 36 | $684.83 |
| 82248 | <1% | 150 | $655.07 | |
| 85049 | <1% | 190 | $650.15 | |
| 86403 | <1% | 61 | $574.90 | |
| 90686 | <1% | 26 | $556.99 | |
| 87420 | <1% | 151 | $506.88 | |
| 73090 | <1% | 32 | $501.79 | |
| 84295 | <1% | 162 | $499.27 | |
| 84520 | <1% | 172 | $482.36 | |
| 77080 | <1% | 13 | $468.37 | |
| 87486 | <1% | 17 | $452.68 | |
| 87581 | <1% | 17 | $452.68 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 92 | $435.98 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 31 | $434.71 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,570 | $420.89 |
| 84550 | <1% | 117 | $417.34 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 17 | $412.09 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 191 | $382.60 |
| 87081 | <1% | 69 | $338.81 | |
| 97035 | <1% | 60 | $314.82 | |
| 73660 | <1% | 25 | $304.80 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 25 | $281.25 |
| 85347 | <1% | 60 | $263.34 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 50 | $241.04 |
| 36430 | <1% | 4,523 | $183.04 | |
| 73620 | <1% | 15 | $157.50 | |
| 87205 | <1% | 46 | $150.97 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 15 | $142.65 |
| 86780 | <1% | 13 | $139.39 | |
| 97032 | <1% | 20 | $138.60 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 21 | $122.16 |
| 82947 | <1% | 42 | $117.04 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 16 | $116.68 |
| 77062 | <1% | 12 | $110.39 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 17 | $99.73 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 281 | $88.75 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 13 | $88.40 |
| 80076 | <1% | 12 | $76.56 | |
| 0300 | <1% | 307 | $75.00 | |
| 85048 | <1% | 26 | $53.63 | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 155 | $48.14 |
| 81015 | <1% | 15 | $41.00 | |
| 74021 | <1% | 13 | $40.68 | |
| 80320 | <1% | 657 | $38.77 | |
| 80329 | <1% | 617 | $15.10 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 596 | $1.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 13 | $0.50 |
| 0306 | 0% | 272 | $0.00 | |
| 0250R | 0% | 119 | $0.00 | |
| 0352 | 0% | 136 | $0.00 | |
| 0324 | 0% | 214 | $0.00 | |
| 0307 | 0% | 246 | $0.00 | |
| 0305 | 0% | 370 | $0.00 | |
| 0410 | 0% | 100 | $0.00 | |
| 0301 | 0% | 370 | $0.00 | |
| 0320 | 0% | 66 | $0.00 | |
| 0730 | 0% | 296 | $0.00 | |
| 0402 | 0% | 102 | $0.00 | |
| 0483 | 0% | 49 | $0.00 | |
| 0351 | 0% | 14 | $0.00 | |
| 0430 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHOMAS, MICHAEL (CEO)
| Provider | Location | Paid |
|---|---|---|
| City of New Bedford | New Bedford, MA | $11.68M |
| State of Delaware | Dover, DE | $1.15M |
| Potential Development Program | Youngstown, OH | $681K |
| Coastal Carolina Care PLLC | Hampstead, NC | $379K |
| John Muir Health | Concord, CA | $300K |
| Alternative Counseling Group, LLC | Chester, VA | $24K |
| Michael R Thomas DDS | Marshall, MN | $289.94 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.